When an executive with a large pharmaceutical company has to decide whether to market a product that might have undesirable side effects for a small percentage of users but that would be beneficial for most of the users the decision turn to on the concept of beneficial to many users versus harmful to few users. The product can be launched to the market only when sufficient care has been taken such that all precautionary measures were in place to protect the few users. From a utilitarian perspective under cost benefit analysis if the product is sold it could benefit to the greatest number of people. But if there is any sort of bad publicity of the product then it will have a high sort of negative effect on the sales such that the sales will reduce drastically to great extent in such scenario more persons could benefit from the decision not to market the product.